Evaluating twenty-years of follow-up after orthotopic liver transplantation, best practice for donor-recipient matching: What can we learn from the past era?

Table 1 Indications of primary liver transplant

	All patients n = 313 (100%)	20-yr survivors n = 157 (50%)	20-yr non- survivors n = 141 (45%)	Ratio1	Lost n = 15 (5%)
Virus-related cirrhosis	92 (29.4%)	46 (29.30%)	39 (27.70%)	1.18	7
Hepatitis B	47 (15.0%)	26 (16.6%)	19 (13.5%)
Hepatitis C	32 (10.2%)	13 (8.3%)	17 (12.1%)
Hepatitis B and D	10 (3.2%)	5 (3.2%)	2 (1.4%)
Hepatitis B and C	3 (1.0%)	2 (1.3%)	1 (0.7%)
Cholestatic/ autoimmune	64 (20.4%)	38 (24.2%)	20 (14.2%)	1.90	6
Alcoholic cirrhosis	50 (16.0%)	23 (14.6%)	27 (19.1%)	0.85
Hepatobiliary malignancy	36 (11.5%)	7 (4.5%)	28 (19.9%)	0.25	1
HCC	27 (8.6%)	6 (3.8%)	20 (14.2%)
CCC	5 (1.6%)	0 (0.0%)	5 (3.5%)
Klatskin tumor	4 (1.3%)	1 (0.6%)	3 (2.1%)
Cryptogenic cirrhosis	29 (9.3%)	15 (9.6%)	13 (9.2%)	1.15	1
Acute liver failure	23 (7.3%)	16 (10.2%)	7 (5.0%)	2.29
Others	19 (6.1%)	13 (8.3%)	6 (4.3%)	2.20

¹ratio of survivors/non-survivors in the respective indication category. HCC: Hepatocellular carcinomas; CCC: Cholangiocellular carcinoma.